Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues:
Total revenues		$ 8,065
Operating expenses:
Research and development	$ 4,516	3,616
General and administrative	2,686	2,590
Total operating expenses	7,202	6,206
Income (loss) from operations	(7,202)	1,859
Total other income (expense), net	47	(107)
Consolidated net income (loss)	(7,155)	1,752
Net loss attributable to noncontrolling interest in Pangu BioPharma Limited	4	1
Net income (loss) attributable to aTyr Pharma, Inc.	$ (7,151)	$ 1,753
Basic, net income (loss) per share	$ (0.51)	$ 0.25
Shares used in computing basic net income (loss) per share	14,103,783	6,881,791
Diluted net income (loss) per share	$ (0.51)	$ 0.25
Shares used in computing diluted net income (loss) per share	14,103,783	6,884,797
License and Collaboration Agreement Revenues [Member]
Revenues:
Total revenues		$ 8,065